TRVI - CIK 0001563880
The table below shows Trevi Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $33.48M | $39.38M | $23.68M | $19.83M | $22.98M | $22.33M |
| SG&A | $15.85M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $12.15M |
| $10.24M |
| $10.07M |
| $9.49M |
| $10.16M |
| Operating income | -$49.33M | -$51.52M | -$33.92M | -$29.91M | -$32.48M | -$32.49M |
| Income tax | -$64.00K | -$30.00K | -$32.00K | -$36.00K | -$21.00K | -$18.00K |
| Net income | -$42.76M | -$47.91M | -$29.07M | -$29.15M | -$33.94M | -$32.76M |
| EPS (diluted) | -$0.32 | -$0.47 | -$0.29 | -$0.45 | -$1.49 | - |